Citigroup’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $18.2K | Sell |
2,055
-3,840
| -65% | -$33.9K | ﹤0.01% | 4369 |
|
|
2025
Q1 | $63.4K | Sell |
5,895
-699
| -11% | -$7.52K | ﹤0.01% | 4043 |
|
|
2024
Q4 | $84.4K | Buy |
6,594
+129
| +2% | +$1.65K | ﹤0.01% | 4077 |
|
|
2024
Q3 | $178K | Buy |
6,465
+3,998
| +162% | +$110K | ﹤0.01% | 3654 |
|
|
2024
Q2 | $71.6K | Buy |
2,467
+83
| +3% | +$2.41K | ﹤0.01% | 3657 |
|
|
2024
Q1 | $106K | Sell |
2,384
-1,403
| -37% | -$62.6K | ﹤0.01% | 3530 |
|
|
2023
Q4 | $147K | Sell |
3,787
-5,900
| -61% | -$229K | ﹤0.01% | 3321 |
|
|
2023
Q3 | $285K | Buy |
9,687
+1,611
| +20% | +$47.4K | ﹤0.01% | 2774 |
|
|
2023
Q2 | $514K | Sell |
8,076
-12,760
| -61% | -$812K | ﹤0.01% | 2716 |
|
|
2023
Q1 | $983K | Buy |
20,836
+7,303
| +54% | +$345K | ﹤0.01% | 2026 |
|
|
2022
Q4 | $939K | Buy |
13,533
+3,200
| +31% | +$222K | ﹤0.01% | 2056 |
|
|
2022
Q3 | $1.51M | Buy |
10,333
+8,733
| +546% | +$1.28M | ﹤0.01% | 1801 |
|
|
2022
Q2 | $208K | Sell |
1,600
-482
| -23% | -$62.7K | ﹤0.01% | 3175 |
|
|
2022
Q1 | $210K | Sell |
2,082
-292
| -12% | -$29.5K | ﹤0.01% | 3377 |
|
|
2021
Q4 | $368K | Buy |
2,374
+2,239
| +1,659% | +$347K | ﹤0.01% | 3251 |
|
|
2021
Q3 | $40K | Buy |
+135
| New | +$40K | ﹤0.01% | 4120 |
|